Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
This study has been completed.
Study NCT00045175 Information provided by National Cancer Institute (NCI)
First Received on September 6, 2002. Last Updated on April 23, 2011
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer
Additional conditions recognized in this trial
Fallopian Tube Neoplasms
Neoplasms, Glandular and Epithelial
Ovarian Neoplasms
Peritoneal Neoplasms
More general conditions related to this trial
Abdominal Neoplasms
Adnexal Diseases
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Fallopian Tube Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Ovarian Diseases
Peritoneal Diseases
Urogenital Neoplasms
Interventions listed in this trial
7-hydroxystaurosporine
topotecan hydrochloride
Additional drug interventions recognized in this trial
Staurosporine
Topotecan
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Sponsors listed in this trial
Princess Margaret Hospital, Canada
National Cancer Institute (NCI)
Back to top of Main Content
